RxDoctor Payments Data

Agnes Quion, MD

Internal Medicine · Victorville, CANPI 1124141122

Payments from drug & device makers

$487in general payments, 2019–2025

Across 18 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$151
  • Sanofi-aventis U.S. LLC$128
  • Novo Nordisk$61
  • AstraZeneca$59
  • Lilly USA, LLC$42
  • GSK$23
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$47597%
  • Education$133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$40,954
Medicare patients
85
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$34,186
OzempicSemaglutide29$29,949
Tresiba Flextouch U-200Insulin Degludec16$27,883
JanuviaSitagliptin Phosphate18$12,877
JardianceEmpagliflozin12$9,110
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$8,372
LinzessLinaclotide12$8,159
XareltoRivaroxaban13$7,985
TradjentaLinagliptin13$6,870
Incruse ElliptaUmeclidinium Bromide12$4,415
Albuterol Sulfate HfaAlbuterol Sulfate129$4,378
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$3,728
Omega-3 Acid Ethyl Esters45$3,373
Epinephrine12$2,676
HumalogInsulin Lispro12$2,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$29,94929 claims
GSKIncruse Ellipta$23$4,41512 claims
Lilly USA, LLCHumalog$42$2,47512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →